Biosimilar Medicare Part B Payment Boost Begins

Part 3: How Adalimumab Biosimilars Will Impact Clinicians

September 20th 2022

The third installment of this 4-part series dives into how providers, administrators, nurses, and pharmacists can prepare for adalimumab biosimilars and what role they can play in patient acceptance and use of biosimilars.

Oncology, Ophthalmology Biosimilars Progress in Europe

September 19th 2022

By Skylar Jeremias

As the United Kingdom adds another oncology biosimilar to its collection, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for another ranibizumab candidate.

Biosimilar Insulin Lispro Shows Similar PK and PD Parameters to Humalog

September 17th 2022

By Skylar Jeremias

A phase 1 study in Japan found similar pharmacokinetic (PK) and glucose pharmacodynamic (PD) parameters between the biosimilar SAR342434 (SAR-Lis, Sanofi) and the Japan-reference insulin lispro (Humalog) in healthy male participants.

The Top 5 Biosimilar Articles for the Week of September 12

September 16th 2022

By Skylar Jeremias

Here are the top 5 biosimilar articles for the week of September 12, 2022.

Contributor: Interchangeability Is a Dispensing Issue, Not a Prescribing One

September 15th 2022

By Gillian Woollett, MA, DPhil

As more biosimilars are granted interchangeability status, 2 representatives from Samsung Bioepis stop misinformation in its tracks by clarifying that the designation will primarily impact pharmacy dispensing instead of prescription habits.

Part 2: For Patients and Employers, 2023 Means a Changed Landscape

September 13th 2022

By Skylar Jeremias

The second part of this 4-part series looks at what patients and employers can expect when adalimumab biosimilars hit the market.

Eye on Pharma: Good News, Bad News for Alvotech; EpiVax Secures FDA Grant for Biosimilar Testing

September 12th 2022

By Skylar Jeremias

As Alvotech’s biosimilars are included in a commercialization deal in the Philippines, the company hits a setback in its quest for FDA approval of its adalimumab biosimilar; the FDA gives EpiVax a $2 million grant to run immunogenicity testing for biosimilars.

What Will Year 1 Look Like for Adalimumab Biosimilars?

September 11th 2022

By Skylar Jeremias

As part of a larger series preparing for the US market entrance of adalimumab biosimilars in 2023, Steven Lucio, PharmD, BCPS, senior principal of pharmacy solutions at Vizient, makes predictions for how the rollout of these biosimilars may play out and offers advice to stakeholders for how to maintain a robust market.

Phase 1 Study Demonstrates Bioequivalence Between Enoxaparin Biosimilar vs Reference Product

September 10th 2022

By Skylar Jeremias

A phase 1 study of an enoxaparin sodium biosimilar Cloti-Xa established similar pharmacodynamics and pharmacokinetic profiles with the reference product (Clexane, Lovenox) in healthy participants.

The Top 5 Biosimilar Articles for the Week of September 5

September 9th 2022

By Skylar Jeremias

Here are the top 5 biosimilar articles for the week of September 5, 2022.